17.32
-1.65%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang Huahai Pharmaceutical Co
Its shares trade on Shanghai under the ticker 600521.SS. It has been listed since 4 March 2003. In the fiscal year to 31 December 2025, it reported revenue of CN¥8.59bn and net income of CN¥266.4m. At that date it held total assets of CN¥21.50bn and shareholders' equity of CN¥9.44bn.
Zhejiang Huahai Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Taizhou, Zhejiang. The company went IPO on 2003-03-04. The firm's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine hydrochloride tablets, risperidone tablets, fosinopril sodium tablets, as well as irbesartan and hydrochlorothinzide tablets, among others. The firm also provides related technical support services. The firm distributes its products in domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 4 Mar 2003
- Employees
- 7,682
- Website
- huahaipharm.com ↗
Leadership
Pay as last reported
- Mr. Hong LiChairman of the Board, since 2019CN¥3.4m
- Mr. Baohua ChenPresident, Director, since 2019CN¥2.2m
- Ms. Mei ZhangChief Financial Officer, Vice PresidentCN¥1.5m
- Mr. Sijia GuoExecutive Vice President, DirectorCN¥2.2m
- Ms. Yanhua MengVice President, General Manager - API DivisionCN¥1.9m
- Ms. Mi XuVice President, General Manager - International Sales CenterCN¥2.3m
- Mr. Yonghua ZhuVice President, Secretary of the Board, Director, since 2007CN¥2.0m
- Mr. Dunyuan ChenVice PresidentCN¥1.9m
- Mr. Qimao ChenVice PresidentCN¥2.2m
- Ms. Hui GangVice PresidentCN¥2.4m
- Mr. Bin HeVice PresidentCN¥5.0m
- Ms. Xiaofang KongVice President
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 62
- Environment
- 82
- Social
- 83
- Governance
- 20
- Direct emissions (scope 1)
- 58,691 t
- Energy emissions (scope 2)
- 349,692 t
- Women in the workforce
- 58.91892%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zhejiang Huahai Pharmaceutical's -pril series products are widely used in domestic markets.
- The company's -sartan series includes irbesartan tablets for hypertension treatment.
- Overseas distribution of products like paroxetine hydrochloride tablets expands market reach.
Weaknesses
- Limited product diversity beyond -pril and -sartan series pharmaceuticals.
- Dependence on domestic market for a significant portion of revenue streams.
- No mention of new product development in recent years.
Opportunities
- Growing demand for hypertension treatments like irbesartan in global markets.
- Expanding overseas markets for pharmaceutical products such as risperidone tablets.
- Increasing focus on technical support services for pharmaceutical distribution.
Threats
- Competition from other pharmaceutical manufacturers in China's domestic market.
- Regulatory changes affecting pharmaceutical distribution in overseas markets.
- Potential supply chain disruptions impacting production of key products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.